LYKALABSNSELyka Labs Limited· PharmaceuticalsMinimalNeutral
Announced Mon, 4 Aug · 13:49 IST

Lyka Labs Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 01, 2025

LYKALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Lyka Labs Limited submitted the voting results and Scrutinizer's Report for its 46th Annual General Meeting held on August 1, 2025, conducted through video conferencing. Out of 28,455 total shareholders, 40 attended via VC (7 promoters and 33 public shareholders). All 9 resolutions were passed with the required majority. Key resolutions included adoption of audited standalone and consolidated financial statements for FY25, re-appointment of Mr. Prashant Godha as director, appointment of Mrs. Archana S Yadav as Independent Director, ratification of Cost Auditor remuneration for FY25 and FY26, appointment of the Secretarial Auditor, approval of Related Party Transactions for FY26, re-appointment of Mr. Yogesh B Shah as Whole-time Director, and introduction of the Lyka Labs Employees Stock Option Scheme 2025. Most resolutions received 99.999% approval, except the Related Party Transactions resolution which received 95.77% support (4.23% against) since related parties abstained from voting on it.

Likely market impact

All AGM resolutions passed cleanly, which is routine and neutral for shareholders. The ESOP Scheme 2025 approval could lead to future share dilution, and the Related Party Transactions approval enables related-party deals for FY26, which investors should monitor for fairness.